Arena Pharmaceuticals to present Phase 2 ralinepag results at ISHLT
Arena Pharmaceuticals announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension, will be presented at the International Society for Heart and Lung Transplantation 2018 Annual Meeting on April 14. The meeting is taking place April 11-14 in Nice, France. "Patients receiving ralinepag experienced improvements in their mortality risk category using three risk scoring methodologies developed and utilized globally," said Dr. Raymond Benza. "These positive data further highlight the potential of ralinepag as an effective treatment of PAH, and I look forward to determining the impact of ralinepag on clinical outcomes in the Phase 3 clinical program." Arena previously announced topline Phase 2 results for ralinepag in PAH in which the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo. Ralinepag also demonstrated numerical improvement in 6-minute walk distance relative to placebo. Adverse events observed in the study were consistent with other prostacyclin treatments for the management of PAH.